RhoGDI╬▒ suppresses growth and survival of prostate cancer cells Article (Faculty180)

cited authors

  • Zhu, Yezi; Tummala, Ramakumar; Liu, Chengfei; Nadiminty, Nagalakshmi; Lou, Wei; Evans, Christopher P; Zhou, Qinghua; Gao, Allen C


  • Treatment for primary prostate cancer (CaP) is the withdrawal of androgens. However, CaP eventually progresses to grow in a castration-resistant state. The mechanisms involved in the development and progression of castration-resistant prostate cancer (CRPC) remain unknown. We have previously generated LNCaP-IL6+ cells by treating LNCaP cells chronically with interleukin-6 (IL-6), which have acquired the ability to grow in androgen-deprived conditions.

publication date

  • 2012

published in

start page

  • 392

end page

  • 8


  • 72